1. Introduction {#sec0005}
===============

Viral infection aggression is linked to both environmental and genetic factors. Although the mortality in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is highly age dependent, the etiology of the coronavirus disease 2019 (COVID-19)-specific mortality in these patients is largely unknown ([@bib0305]). SARS-CoV-2 has a size of 60−140 nm. Nasal or saliva droplet aerosols from infected individuals provide an efficient means of transport for the viral particles, as well as attachment to suspended fine particles in air ([@bib0475]). Positive correlations of PM2.5, PM10, nitrogen dioxide (NO~2~) and ozone (O~3~) levels with cases confirmed with new COVID-19 underlines the how air pollution is assisting in the propagation of SARS-CoV-2 infection ([@bib0530]). Angiotensin-converting enzyme-2 (ACE2) protein provides the host cellular entry point for SARS-CoV-2 ([@bib0025]). Thus, the relationship between ACE2 and SARS-CoV-2 is pivotal in the infection process ([@bib0140]; [@bib0145]; [@bib0375]). If these receptors are inhibited by the angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type-I receptor blockers (ARBs), a concomitant fall in inflammation might occur via diminished viral invasion of tissues such as the lungs and the heart ([@bib0385]). Conversely, upregulation of ACE2 or higher ACE2 gene expression may increase susceptibility to infection by SARS-CoV-2, and COVID-19 disease severity ([@bib0035]). Tobacco smokers have a greater predisposition (1.4 fold) to developing severe symptoms of COVID-19. This often necessitates their entry into intensive care units (ICU), alongside concomitant mechanical ventilation; moreover, their death rate is approximately 2.4 times that of non-smokers ([@bib0150]; [@bib0455]). Among adults aged more than 65 years approximately 89 % suffer from one or more underlying comorbidities, including obesity (48 %), cardiovascular disease (28 %), hypertension (50 %) and diabetes mellitus (28 %) as well as chronic lung disease (35 %) ([@bib0135]). These comorbidities show a trend towards increased disposition to COVID-19 severe disease, but no specific significant association could be shown with active smoking and obesity and severity particularly in Chinese patients ([@bib0290]; [@bib0460]). However, among the patients admitted to ICU for SARS-CoV-2, requiring invasive mechanical ventilation (IMV), the proportion of obese patients is high. This increase in the rate of patients who need IMV is significantly linked with being male and possessing a high body mass index (BMI) ([@bib0425]).

Recently, the low mortality rate in patients with acute respiratory distress syndrome (ARDS) with obesity and morbid obesity is defined as the obesity paradox ([@bib0020]). To date it is unclear if this paradox is not broken by COVID-19. Whilst they can suffer less from severe COVID-19 infection, obese patients are nevertheless subject to the comorbidities associated with being overweight and they are subsequently more difficult to treat due to these factors ([@bib0235]). It is thought that obesity or excess ectopic fat deposition may be the underlying risk factors for severe COVID-19, because of their comorbid conditions, such as cardiovascular diseases, insulin resistance, adipose tissue inflammation and detrimental effects on lung function. These risk factors are strongly associated with mortalities from COVID-19 and are more frequent among smokers. Indeed, obesity and smoking both definitely upregulate ACE2 receptor ([@bib0035]; [@bib0100]). Interestingly, obesity, air pollution and smoking-associated risk factors share underlying pathophysiology related to the renin-angiotensin system (RAS) in SARS-CoV-2 infection.

2. Exposure to SARS-CoV-2 {#sec0010}
=========================

SARS-CoV-2 is single strand RNA virus which uses type 1 transmembrane spike (S) glycoprotein projections as a lock-and-key combination to breach cells. The viral glycosylated cell surface protein can be further classified as using two (S1 and S2) functional domains which manage the entry process ([Fig. 1](#fig0005){ref-type="fig"} ). Initial ACE2 receptor cell entry is operated by domain S1 ([@bib0270]), whilst S2 sets up cell and virus membrane fusion which is necessary for full infiltration into the cell ([@bib0070]). The ACE2 protein is present in abundance around the body, such as the small intestine, as well as on lung epithelia and particularly on lung type-2 pneumocytes. Thus, increase in ACE intensity effectively facilitates a most flexible and ubiquitous pathway into cells for SARS-CoV-2 ([@bib0170]). After SARS-CoV-2 invasion occurs due to the interaction of its spike protein with a receptor furin-cleavage site ([@bib0180]; [@bib0490]), a transmembrane protease, serine 2 (TMPRSS2) then separates ACE2 from SARS-CoV-2; this has the effect of accelerating the progress of the infection ([@bib0185]; [@bib0190]). Indeed, the whole likelihood of the risk of contracting a severe infection, as well as progressing towards a poor clinical outcome is governed by the ACE2-COVID-19 receptor ligand interaction ([@bib0005]). Affinity-modifying agents of ACE2, such as NO~2~ and nicotine could potentially disrupt glycosylation on the spike protein, thus interfering with the infection process. In this context, RAS can modulate infection severity ([@bib0005]; [@bib0330]; [@bib0355]). As mentioned above, in countries where NO~2~ pollution was high, COVID-19 course was significantly severe ([@bib0005]).Fig. 1The mechanism of receptor-ligand interaction and its impact on the enhanced risk of death due to SARS-CoV-2 infection.In the renin angiotensin system, ACE cleaves Ang I to produce Ang II. Ang II action is mediated by the AT1R. SARS-CoV-2 uses the ACE2 as a receptor for entry into the cell. Coronaviruses use the surface spike (S) glycoprotein on the coronavirus envelope to attach host cells and mediate host cell membrane and viral membrane fusion during infection. The spike protein includes two regions, S1 and S2. The receptor binding domain is located in the S1 region. SARS-CoV attaches the human host cells through the binding of the receptor binding domain protein to ACE2. The expression of ACE2 and the balance of Ang II/Ang 1--7 influence the course of the disease. ACEI and ARBs cause the increase in the formation of Ang 1--7 from Ang II via increased ACE2. The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing. Accordingly, ACE2 may be upregulated due to the NO~2~ associated air pollution, and ACEIs. Nicotine has dual action by enhancing ACE and down-regulating ACE2 *(Abbreviations*. *ACE: angiotensin-converting enzyme; ACE2: angiotensin-converting enzyme II; ACEI: angiotensin-converting enzyme inhibitors; Ang I: angiotensin I; Ang II: angiotensin II; ARB: angiotensin II type-I receptor blocker; AT1R: angiotensin II receptor type 1; NO~2~: Nitrogen dioxide; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2*).Fig. 1

In addition to ACE2 receptors, two different coronavirus receptor proteins, toll like receptor (TLR) and dipeptidyl peptidase-4 (DPP4) have vital roles in the pathways regulating the transduction on metabolic signals across metabolic processes, ranging from fundamental ones such as glucose homeostasis through to organ function modulation in the kidney, heart and the immune system and its inflammatory activity ([@bib0090]). As mentioned above, SARS-CoV-2 exploits ACE2 to begin and then propagate its progression towards ARDS. Existing cardiovascular pathology and drug-mediated RAS inhibition which cause a rise in ACE2 expression may essentially increase the vulnerability of lung and heart to SARS-CoV-2 virulence. On the other hand, it has been reported that corona viruses during their infection process can cause accumulation of Angiotensin II (Ang II) through the blocking of the ACE2 receptors ([@bib0175]).

Several hypotheses have been proposed regarding the effect of ACEI and ARBs on SARS-CoV-2 infection. Proteolytic cleavage processes, as well as endocytosis are all activated by viral binding and these unit to attenuate ACE2 activity. Unfortunately, SARS-CoV-2 not only effectively exploits a critical and irreplaceable system that is ACE2 to enter and multiply in the host ([@bib0145]), but its ACE2 binding allows it to evade immune surveillance. The engulfment of ACE2 provides the virus access to the host cellular infrastructure, hence viral proliferation and immune evasion are inextricably linked with regard to successful and potentially devastating infection ([@bib0035]). In normal circumstances, the RAS system is antagonized by ACE2, which is protective in terms of the development of systemic damage due to hypertension, diabetes, and cardiovascular disease. SARS-CoV-2 utilizes the ACE2 receptor to invade human alveolar epithelial cells. Indeed, a bad prognosis has been shown to be linked to ACE2 receptor activity, as well as the presence of secondary ARDS and other factors such as age, and sex and multiple comorbidities ([@bib0055]). Collectively, it is thought that dysfunction of the RAS is a common pathology seen in SARS-CoV-2 infected obese patients and smokers, however it has not been evaluated in detail.

3. The effect of tobacco smoke and nitrogen dioxide exposure in COVID-19 {#sec0015}
========================================================================

Smokers figure disproportionately highly in the numbers of severe COVID-19 victims in comparison to the non-severe patients ([@bib0225]). Their ICU admissions and subsequent IMV requirements are also considerably higher. Indeed, a fatal outcome is more likely with smokers ([@bib0150]; [@bib0525]). Compounded by the smoking, the presence of obstructive pulmonary disease (COPD), cardiovascular pathology and diabetes is greater among severe cases ([@bib0525]). In one study, (1099 COVID-19 patients), of the 19 % of patients severely affected, just under 17 % were current smokers and 5.2 % were former smokers. In another report, patients who had severe disease, where they were admitted to ICU, ventilated and/or who had fatal outcomes, about a quarter (25.5 %) smoked and 7.6 % were former smokers ([@bib0150]). Conversely, Liu et al. reported that among an adverse outcome group of patients, a smoking history was nine-fold more prevalent, than the group that showed improvement or stabilization. In these patients, age, history of smoking, respiratory failure, low albumin and high C-reactive protein were identified as the risk factors that lead to the acceleration of disease progress to pneumonia (Khot and Nadkar, 2020; [@bib0015]; [@bib0460]; [@bib0485]). In only two studies from total of five, 288 of 1399 COVID-19 patients were diagnosed with severe disease. In these patients COVID-19 progression was driven by smoking history, while the others were not thus associated ([@bib0150]; [@bib0205]; [@bib0290]; [@bib0460]; [@bib0505]). The rate of ARDS development in SARS-CoV-2-infected individuals that already had pneumonia was around 50 % ([@bib0485]). Patients who are likely to die from the infection suffer pulmonary oedema and bilateral diffuse alveolar damage which is caused by significant inflammatory infiltrates ([@bib0435]). Unfortunately, in these patients, obesity has serious consequences. In fact, ARDS from a number of causes, is often a major reason for significantly overweight (class III obese) patients being admitted to ICUs, where they are ventilated, which also occurs with COVID-19 patients ([@bib0320]). Multiple organ failure is usually cause of mortality in both morbidly obese and COVID-19 patient groups ([@bib0030]).

Tobacco smoke promotes exposure to environmental NO~2~, benzene, and 1,3-butadiene ([@bib0160]), and ambient air pollution associated with NO~2~ causes an increase in Ang II-binding to its receptor by upregulating ACE activity by up to 100-fold. Meanwhile, nicotine exhibits a dual effect by increasing ACE expression and causing a fall in ACE2 activity ([@bib0005]; [@bib0330]). Nicotine upregulates activity and expression of renin, ACE and Ang II type I receptor (AT1R). Interestingly, nicotine can also switch off compensatory expression and activity of ACE2 and Ang II type 2 receptor (AT2R) ([Fig. 1](#fig0005){ref-type="fig"}). Tobacco combustion products as well as nicotine administration itself promotes angiotensin I (Ang I) conversion to Ang II via promoting plasma ACE activity ([@bib0345]). Tobacco smoke exposure also promotes lung inflammation, thus increasing mucosal inflammation, inflammatory cytokines and tumor necrosis factor (TNF)-alpha (TNF-α) expression, as well as increasing permeability in epithelial cells, mucus production, and impaired mucociliary clearance ([@bib0440]). Similarly, the binding of the virus to the TLR promotes pro- interleukin (IL)-1β levels, which is in turn cleaved by caspase-1. As soon as this occurs, inflammasome activation is followed by the formation of mature IL-1β; this is itself an important promotor of inflammatory processes in the lung, as well as fever and fibrosis ([@bib0065]). For the reasons described above, smoking increases the severity of COVID-19 associated inflammatory response. COVID-19 ICU patients suffer high systemic inflammatory responses, which are evidenced by elevated plasma levels of IL-2, IL-6, IL-7, IL-10, granulocyte colony-stimulating factor (GC-SF), interferon-gamma (IFN-γ)-inducible protein (IP10; CXCL10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 alpha (MIP1A), and TNF-α ([@bib0205]). The proportions of IFN-γ yielding CD8 + T and CD4 + T cells rise in the seriously COVID-19 patients compared with mild cases. It is likely that the so-called inflammatory 'cytokine storm' in seriously ill patients is promoted by CD8+ and CD4 + T cells ([@bib0120]; [@bib0220]; [@bib0515]). It is claimed that lower counts of T lymphocyte subsets, (CD3+, CD4+, CD8+) and B-cells are associated with higher risks of in-hospital death of COVID-19 ([@bib0480]). Hence, the survival of the most seriously ill individuals is strongly predicated on the attenuation of the cytokine storm. The damage caused by the storm is orchestrated by IL-6, which presents a pharmacological target, for which there is already a candidate, tocilizumab (TCZ). This agent inhibits the IL-6 receptor (IL-6R), and can curtail IL-6 signal transduction ([@bib0015]; [@bib0295]; [@bib0045]). In fact, TCZ was approved in 2017 by the Food and Drug Administration (FDA) for the treatment of life-threatening cytokine-release syndrome, which is commonly associated with respiratory symptoms ranging from cough and tachypnea to ARDS ([@bib0010]). Interestingly, high-lactate dehydrogenase, C-reactive protein and IL-6 are observed in patients with severe COVID-19, as in cytokine release syndrome. Although at the time of writing it is yet to gain FDA approval for use in COVID-19, in preliminary trials more than half of patients with the disease exhibited a gradual reduction in IL-6 levels following TCZ administration ([@bib0295]; [@bib0415]; [@bib0515]; [@bib0510]). The FDA has approved the initiation of a Phase III trial with TCZ (COVACTA) in patients with severe pneumonia as of April 2020 ([@bib0060]).

In severe COVID-19, provided patients had CD4 + T cells, CD8 + T cells, IL-6, and IL-10 within normal values, their survival was more likely ([@bib0410]). Notably, pre-existing chronic obstructive pulmonary disease (COPD) and current tobacco use make a poor outcome with COVID-19 much more likely ([@bib0360]; [@bib0370]). Tobacco smoking is a powerful driver of all infectious lung pathology. Smokers are more than a third likely to suffer from influenza compared with non-smoking ([@bib0260]). Smoking is strongly associated with COPD in the developed world, although poor local air-quality due to the increasing atmospheric pollution is also significant COPD promotors in developed and developing countries. Smoking remains the fourth leading cause of death in the world ([@bib0470]). The World Health Organization enounces that respiratory comorbidities from all sources, including tobacco, are associated with a high percentage of COVID-19 related deaths ([@bib0470]; [@bib0500]).

Smokers also exhibit increased ACE2 gene expression in type-2 pneumocytes, alveolar macrophages, particularly at the apical end of the small airway epithelium, which is not seen in those who do not use tobacco. COPD itself promotes ACE2 expression thus providing ample targets for SARS-CoV-2 cell entry ([@bib0035]; [@bib0050]). So significant lung damage with tobacco use promotes the risk of COVID-19 and progression to severe disease ([@bib0035]; [@bib0220]). Immune evasion of virus as mentioned above, may increase viral adhesion to the target host cells for relatively longer periods. This elevates the carrier status of the host due to their high local tissue viral load, which will promote the spread of the infection ([@bib0035]). Ang II and AT1R, are key constituents of the RAS, and they regulate mitogen-activated protein kinase (MAPK) and Janus kinase (JAK) pathways ([@bib0245]). Lung injury is thought to be promoted by compromised RAS activity as this is linked with local pro-inflammatory cytokine production. Indeed, ACEI, as well as Ang II receptor antagonists are capable of ameliorating lung damage in experimental models and this suggests that RAS activity is implicated. Thus, it could be proposed that those drugs may treat diffuse parenchymal lung disease successfully ([@bib0315]). Cigarette smoke exposure increases pulmonary ACE and ACE2 activity, however loss of ACE2 increases Ang II by inducing the ACE activity ([@bib0210]). As mentioned earlier, factors that promote ACE2 increase risk of severe COVID-19 ([@bib0125]). Any reduction in ACE2 activity restricts available virus-cell binding sites and may be protective in smokers. Unfortunately, if ACE2 function diminishes due to a high level of viral attack and binding, this would cause endocytosis, along with proteolytic cleavage; these events may lead to increase in respiratory distress ([@bib0005]; [@bib0145]).

4. The effect of obesity on the course of COVID-19 {#sec0020}
==================================================

Experience with obesity-related mortality with H1N1 influenza illustrated that much more forceful treatment of obese COVID-19 patients was required than was originally envisaged ([@bib0085]). Obesity not only enhances the severity of influenza infection but also impacts viral diversity ([@bib0195]). More than 70 % of COVID-19 patients who require intensive care have a high rate of obesity ([@bib0310]). In patients aged less than 60 years in New York City, the progression of obesity towards morbid obesity more than doubled the risk of admission to critical care unit, compared with those with lower BMIs (\<30 kg/m^2^) ([@bib0285]). It has been established that morbid obesity doubles the risks of poor outcomes compared with those who are not clinically obese ([@bib0095]). Among the various patient comorbidities with COVID-19, the most common is hypertension (21 %), followed by diabetes (11 %) and around 7 % suffer from underlying cardiovascular problems, all of which promote the risk for hospitalization and death in COVID-19 patients ([@bib0335]; [@bib0430]). In a series of COVID-19 deaths in a cohort of patients in Wuhan, China 42 % of the fatalities were diabetics ([@bib0080]). The condition of obesity related fatty liver disease increases the risk of severe COVID-19 by six-fold. This powerful association between fatty liver disease and risk of a fatal outcome with COVID-19 was valid even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidemia ([@bib0240]). Essentially, a lipotoxic state is induced by habitual overload of dietary saturated fatty acids (SFAs), which activates TLR 4 expressed on several immune cells, such as neutrophils, macrophages and dendritic cells ([@bib0105], [@bib0110]; [@bib0400]). High fat diet significantly disrupts adaptive immune response, while increasing innate immune activation. This promotes the chronic inflammation and may cause the host defense become vulnerable against viral pathogens ([@bib0040]). Consequently, in obese patients, viral pools can lodge in adipose tissue and promote shedding, immune activation, and chronic excessive cytokine release ([@bib0405]).

Mechanistically, disorders such as diabetes, cardiovascular disease and hypertension share same underlying pathophysiology related to the RAS in both COVID-19 and obesity ([@bib0175]). Excessive adipose tissue in obesity secretes Ang II, which is a hormone with inflammatory properties and is generated in the RAS pathway. Obesity and insulin resistance are strongly linked with RAS activity. Furthermore, oxidative stress and inflammatory response along with mitochondrial dysfunction modulate the function of RAS ([@bib0380]). In addition, diabetic kidney damage is promoted by the renal RAS activation through endoplasmic reticulum stress, which is in turn induced by SFAs ([@bib0275]). Moreover, increased RAS activity in obesity initiates a series of interrelated pathological events. These include reduction of insulin secretion and sensitivity, as well as fostering a rise in arterial pressure. In all these conditions AT1R is upregulated. Contrarily, AT1R blockade improves hyperglycemia, hypertension and peripheral tissue insulin sensitivity ([@bib0395]). Once RAS function is compromised, it causes widespread dysfunction in most tissues, through the deleterious processes described above ([@bib0380]).

At the cellular level, renin forms angiotensin I (Ang I) from angiotensinogen. ACE cleaves Ang I forming Ang II ([@bib0255]). Ang II acts at cell surface type I G protein-coupled receptors, AT1Rs then promote a pathological cascade including insulin resistance, oxidative stress, inflammation and vasoconstriction ([@bib0300]). Reduction of the phosphoinositol-3 kinase (PI3K) activity due to elevated free fatty acids (FFAs) levels is potentiated by Ang II and consequently insulin-stimulated glucose uptake is increased by RAS inhibition. Blockade of the AT1R has been shown to stimulate the differentiation of adipocytes that store FFAs, of which leads to reduced plasma FFA levels and decreased insulin resistance ([@bib0265]). RAS activity can also be upregulated by insulin resistance. This can in turn promote a series of linked pathophysiological issues such as inflammatory diseases, as well as the metabolic disorders associated with obesity ([@bib0340]). In fact, the major effects of Ang II are mediated by AT1R and AT2R. Overexpression of angiotensinogen increases adiposity, which is seen through hypertrophy of adipocytes, inflammation and increased resistance to insulin. RAS inhibition can ameliorate and even reverse these obesity related alterations in adipose tissue ([@bib0350]). The fall in glucose-mediated insulin secretion is linked with lower pancreatic insulin content and upregulated AT1R protein expression in obesity. Essentially, β-cell dysfunction is strongly associated with AT1R upregulation, which accelerates glucose intolerance and insulin resistance, through a decrease in plasma glucagon-like peptide-1 (GLP-1). In contrast, RAS blockade induces improvement in β-cell function and insulin sensitivity ([@bib0390]; [@bib0450]). The general progression of atherosclerotic disease is also influenced by RAS, as well as its primary mediator Ang II. The mechanisms of this process include inflammation, disruption of fibrinolytic balance and endothelial dysfunction. The inhibitors of RAS such as ACEI and angiotensin receptor blockers act either by depleting the generation of Ang II or by blocking the binding of Ang II to its receptors ([@bib0215]). ACE2 is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels. The expression of ACE2 is substantially increased in patients with type 2 diabetes, who are treated with ACEI and ARBs ([@bib0490]). Similarly, treatment of hypertension with ACEI and ARBs, results in an upregulation of ACE2 ([@bib0280]). Consequently, the increased expression of ACE2 would facilitate COVID-19 due to spreading of SARS-CoV-2 ([@bib0125]). Since the ACE2 protein is the receptor that facilitates corona virus entry into cells, the notion that treatment with RAS blockers might increase the risk of developing a severe and fatal ARDS in COVID-19 infection has been popularized. Interestingly, the contention that the presence of ACEI or AT1R blockers promote coronavirus infection through upregulating ACE2 expression in either animals or humans is not currently supported ([@bib0075]). On the contrary, ACEI in addition to RAS inhibitors in COVID-19 patients with hypertension actually can improve clinical outcome ([@bib0325]). The use of selective AT1R antagonists in the treatment of hypertension is a useful concept. Firstly, selective AT1R blockade targets the final common pathway for all major detrimental cardiovascular actions of Ang II, and secondly; circulating Ang II levels, which increase during AT1R antagonist treatment, will be free to act only at unopposed AT2R. Also, RAS is disrupted by ACEI through blocking Ang I to Ang II conversion ([@bib0445]).

In females it is thought that adipocyte ACE2 has an ameliorating effect with regard to blood pressure response to systemic Ang II, as well as to obesity ([@bib0420]). Compared with females, despite the males lower adiposity ([@bib0165]; [@bib0230]), hypertension is more frequent in men compared with women until menopause, and then the situation reverses ([@bib0130]). Asian men show a greater expression of ACE2 compared with women and other ethnicities, which might explain the increase in the prevalence of COVID-19 in this subgroup of patients. In this regard, the sex-balance for COVID-19 infection is in favour of men (67 %), rather than women. Considering an overview of available studies, more than half of COVID-19 patients in 552 hospitals were reported to be male, which supports the idea that a sex predisposition to COVID-19 does exist, with men being more susceptible ([@bib0150]; [@bib0505]; [@bib0045]; [@bib0225]; [@bib0495]). Moreover, the sustained high levels of Ang II in these male patients strongly correlated with mortality ([@bib0200]). In addition, obese female subjects compared with lean females have greater adipose tissue expression of ACE2 ([@bib0155]). In a mouse model, reduced ACE2 expression drives obese females toward hypertension equivalent to obese males. The Ang-(1--7) to Ang II, conversion equilibrium is controlled by ACE2. This is sex-specific and differently promotes the development of obesity related hypertension in males and females. ACE2 mRNA abundance is driven upwards by 17-β estradiol in adipocytes via the estrogen receptor alpha (ERα) ([@bib0155]). Typically, adipocytes are the prevalent source of ACE2 for the development of obesity related hypertension. Unexpectedly, modulation of ACE2 by estrogen may protect against obesity related hypertension in obese females. Therefore, ACEI are not recommended for obese women. Increasing body weight and loss of vascular protection mediated by the abrupt loss of estrogen may contribute to the development of hypertension in post-menopause ([@bib0115]; [@bib0420]). Systemic ACE2 activity levels are negatively correlated with BMI and blood pressure in female essential hypertension patients ([@bib0520]). Since previous findings demonstrated that ACE2 activity was increased by obesity in adipose tissue of female, but not male animals ([@bib0155]), then these results suggest that obesity per se may introduce sex- and tissue-specific regulation of ACE2.

In contrast, food restriction by between 20 % and 40 % improves metabolic profile, ameliorates inflammatory status and down-regulates the RAS ([@bib0365]). Interestingly, the available data does not support a deleterious effect of RAS blockers in COVID-19. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic ([@bib0250]). Combining ACEI and ARBs to provide more extensive RAS inhibition may provide greater efficacy for end-organ protection ([@bib0465]).

5. Conclusion {#sec0025}
=============

COVID-19 patients have increased Ang II compared to healthy people. Obesity, air pollution and smoking are associated risk factors which share underlying pathophysiology related to the RAS in SARS-CoV-2 infection. Air pollution via the interference of NO~2~ increases the ACE activity. Meanwhile, nicotine exhibits dual effect on RAS. Obese adipose tissue synthesizes excess Ang II, thus the combination of an AT1R antagonist with an ACEI for more complete blockade of the RAS may be a rationally viable therapeutic strategy in obese COVID-19 patients. In this context, using ACEI or ARBs potentially contribute to the improvement of clinical outcomes of COVID-19 patients.
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